How to appeal an Aetna autoimmune cytopenias (itp + aiha) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.

What Aetna's policy requires for autoimmune cytopenias (itp + aiha)

Cited policy: Aetna CPB on Tavalisse (Fostamatinib) for Chronic ITP

Chronic ITP. Insufficient response to >=1 prior ITP therapy (corticosteroids, IVIG, splenectomy, rituximab, or TPO-RA). Hematologist Rx. Starting dose 100 mg BID, escalate to 150 mg BID. Reauth 12 wk with platelet response.

How Aetna denies autoimmune cytopenias (itp + aiha) — and how to counter it

Where Aetna pushes back: 1) Experimental / unproven; 2) Must fail BOTH eltrombopag AND romiplostim first; 3) Must fail splenectomy before fostamatinib.

Counter-arguments that hold up: Tavalisse FDA-approved Apr 17, 2018 for chronic ITP after >=1 prior therapy — explicitly NOT step-after-TPO-RA. Pivotal FIT-1 + FIT-2 + FIT-3 (Bussel BJH 2018) pooled stable platelet response (>=50 x10^9/L on >=4 of last 6 visits) 18% vs 2% placebo. Mechanism — SYK inhibition of macrophage Fc-gamma phagocytosis — distinct from TPO-RAs (megakaryocyte stimulation), supporting rational substitution. ASH 2019 + ICR 2019 endorse fostamatinib as second-line option. No guideline requires sequential TPO-RA failure before SYK-i.

What Aetna typically denies for autoimmune cytopenias (itp + aiha)

Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For autoimmune cytopenias (itp + aiha), expect:

• UM-2575 medical necessity denials
• Prior auth absent
• Step therapy on specialty drugs
• Out-of-network ER reduction

Treatments most often denied in this category

These are the autoimmune cytopenias (itp + aiha) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Steroids (pred / dex)
• IVIG
• Anti-D (WinRho)
• Rituximab (off-label)
• Promacta (eltrombopag)
• Nplate (romiplostim)

How to submit the appeal to Aetna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
3. File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.